Advertisement
Advertisement

Pfizer to spend $120 million to boost U.S. COVID pill manufacturing

By:
Reuters
Published: Jun 6, 2022, 15:38 UTC

(Reuters) - Pfizer Inc said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.

Pfizer logo is seen at the entrance to Pfizer UK headquarters in Tadworth

(Reuters) – Pfizer Inc said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.

Use of the pill, Paxlovid, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.

Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.

(Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Did you find this article useful?

Advertisement